Gastrointestinal Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOX

Incidence of toxicity for most diseases are reported on the presence or absence of relative adverse effects but in case of chemotherapy induced toxicity i.e. nausea, vomiting, stomatitis or diarrhea, it is limited to the report of severity of the symptoms (Carlotto et al., 2013). Oral and gastrointestinal mucositis/stomatitis are frequently reported in myelosuppressive chemotherapy of solid cancer (Schultheis et al., 2013). Colorectal cancer (CRC) is the third most frequent and top commonly diagnosed solid cancer in the world (Halit et al., 2012; Joanne et. al., 2013). The main therapeutic intervention for CRC is surgery (Dogan et al., 2011), whereas, most common and effective chemotherapeutic regimen in CRC is FOLFOX (Qi et al., 2013). Oxaliplatin in combination with 5FU/LV has effectively increased the progression free survival in patients of colorectal carcinoma (Bano et al., 2013a). The severity of gastrointestinal adverse effects associated with 5FU/LV chemotherapy is increased with the incorporation of oxaliplatin in the regimen (Bano and Najam, 2013b; Bano et al., 2013c) FOLFOX4 is associated with grade 3 or 4 diarrhea (Uncu et al., 2013) and nausea/vomiting (Lee et al., 2013) which is endured with effective supportive